[1]蔡晶,韩娜,张芳,等.舒尼替尼联合多西他赛对A549细胞增殖、凋亡、细胞周期及cmet、mek、erk mRNA表达的影响[J].郑州大学学报(医学版),2013,(03):330.
 CAI Jing,HAN Na,ZHANG Fang,et al.Effects of sunitinib and docetaxel on proliferation,apoptosis,cell cycle and expressions of cmet, mek and erk mRNA in A549 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(03):330.
点击复制

舒尼替尼联合多西他赛对A549细胞增殖、凋亡、细胞周期及cmet、mek、erk mRNA表达的影响
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2013年03期
页码:
330
栏目:
论著
出版日期:
2013-06-20

文章信息/Info

Title:
Effects of sunitinib and docetaxel on proliferation,apoptosis,cell cycle and expressions of cmet, mek and erk mRNA in A549 cells
作者:
蔡晶韩娜张芳方黎郑鹏远张中冕#
郑州大学第二附属医院肿瘤科 郑州 450014
Author(s):
CAI Jing HAN Na ZHANG Fang FANG Li ZHENG Pengyuan ZHANG Zhongmian
Department of Oncology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014
关键词:
肺癌多西他赛舒尼替尼cmetmekerk增殖凋亡细胞周期A549细胞
Keywords:
lung cancerdocetaxelsunitinibcmetmekerkproliferationapoptosiscell cycleA549 cell
分类号:
R734.2
摘要:
摘要目的:探讨舒尼替尼单药以及联合多西他赛不同顺序给药对A549细胞增殖、凋亡、细胞周期及cmet、mek、erk mRNA表达的影响。方法:取对数生长期的A549细胞进行以下实验。实验Ⅰ:对照组加入RPMI 1640培养基;多西他赛单药组给予多西他赛(终质量浓度16 mg/L,下同);舒尼替尼单药组给予舒尼替尼(终浓度7.5 μmol/L,下同);舒尼替尼+多西他赛组,加入同时含两药的培养液。实验Ⅱ:多西他赛→舒尼替尼组(D→S组)先加入100 μL含多西他赛的培养液培养24 h,洗脱,再加入100 μL含舒尼替尼的培养液继续培养24 h;舒尼替尼→多西他赛组(S→D组),同上反向处理。采用MTT法检测以上各组细胞增殖抑制率,流式细胞术检测细胞周期分布及细胞凋亡,RTPCR检测A549细胞cmet、mek、erk mRNA的表达水平。结果:Ⅰ:联合用药组较单独用药组细胞增殖抑制率、晚期凋亡率和总凋亡率升高,S期细胞减少,erk表达上调(P<0.05)。Ⅱ:D→S组较S→D组细胞增殖抑制率和凋亡率升高,G0/G1期细胞减少,S期、G2/M期细胞增多,cmet、mek mRNA表达下调,erk mRNA表达上调(P<0.05)。结论:舒尼替尼和多西他赛均能抑制A549细胞的生长,联合用药优于单独用药;多西他赛后序贯舒尼替尼能产生明显的协同效应,效果优于舒尼替尼后序贯多西他赛。
Abstract:
AbstractAim: To investigate the effects of sunitinib combined docetaxel under different administration schedules on the proliferation,apoptosis and cell cycle of A549 cells as well as the expressions of cmet, mek, and erk mRNA in A549 cells.Methods:Ⅰ:Control group was added RPMI 1640 medium only, docetaxel only (final concentration of 16 mg/L, the same below), sunitinib only (final concentration of 7.5 μmol/L, the same below), and the sunitinib+docetaxel group was added RPMI 1640 medium containing 2 drugs at the same time.Ⅱ:Docetaxel sequential sunitinib group(D→S) incubated with 100 μL RPMI 1640 medium containing docetaxel for 24 h, followed by replacing the docetaxel with 100 μL RPMI 1640 medium containing sunitinib for another 24 h. Sunitinib sequential docetaxel group(S→D), reversed the above process. MTT assay was used to measure proliferation inhibition of each group. Flow cytometry was used to analyze the alteration of cell apoptosis and cycle in A549 cells. RTPCR was employed to measure the expressions of cmet, mek, and erk mRNA in the cell line. Results: Ⅰ:Compared with single drug treatment, in combination treatment group, cell proliferation inhibition rate,late apoptosis rate,and total apoptosis rate increased; S phase cells decreased; the mRNA expression level of erk increased(P<0.05).Ⅱ:Compared with S→D group, in D→S group, cell proliferation inhibition rate and apoptosis rate increased; G0/G1 phase cells decreased, and S and G2/M phase cells increased; the mRNA expression levels of cmet and mek decreased, but that of erk increased(P<0.05). Conclusion: Sunitinib and docetaxel could inhibit the growth of A549 cell. Combination treatment is better than single drug treatment. The way using docetaxel before sunitinib shows obvious synergistic effect.

参考文献/References:

[1]Greenlee RT, HillHarmon MB,Murray T, et al. Cancer statistics, 2001[J]. CA Cancer J Clin, 2001, 51(1):15
[2]DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011[J]. CA Cancer J Clin, 2011, 61(6):409
[3]Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumour activities[J]. Ann Oncol, 2007, 18(Suppl 10):x3
[4]Montero A, Fossella F, Hortobagyi G, et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data [J]. Lancet Oncol, 2005, 6(4):229
[5]Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmallcell lung cancer previously treated with platinumcontaining chemotherapy regimens. The TAX 320 NonSmall Cell Lung Cancer Study Group[J]. J Clin Oncol, 2000,18(12): 2354
[6]Wasylyk C, Zheng H, Castell C, et al. Inhibition of the RasNet (Elk3) pathway by a novel pyrazole that affects microtubules [J]. Cancer Res, 2008,68(5):1275
[7]Rajalingam K,Rudel T. RasRaf signaling needs prohibitin[J]. Cell Cycle, 2005, 4(11):1503
[8]Rajalingam K, Wunder C, Brinkmann V, et al. Prohibitin is required for Rasinduced RafMEKERK activation and epithelial cell migration [J]. Nat Cell Biol, 2005, 7(8):837
[9]Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity [J]. Cell Signal, 2001,13(11):777
[10]Zhu XF, Liu ZC, Zeng YX. Tyrosine kinase receptormediated signal transduction and cancer treatment[J]. Yao Xue Xue Bao, 2002, 37(3):229

相似文献/References:

[1]王玉珍,吴逸明,李伟辉,等.热休克蛋白70hom基因+2 437(T/C)位点基因多态性与肺癌的关系*[J].郑州大学学报(医学版),2010,(02):219.
 WANG Yuzhen,WU Yiming,LI Weihui,et al.Heat shock protein 70hom gene+2 437(T/C) polymorphism and susceptibility to lung cancer in Chinese Han population[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(03):219.
[2]刘艳华),王玲),王彦平),等.膳食因素与肺癌关系的病例对照研究[J].郑州大学学报(医学版),2009,(06):1260.
 LIU Yanhua),WANG Ling),WANG Yanping),et al.A casecontrol study on relationship between dietary intake and relative factors and lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(03):1260.
[3]马会军),李耀军),牛松涛),等.非小细胞肺癌40例介入治疗体会[J].郑州大学学报(医学版),2009,(05):1106.
[4]张菊娥)△,郭茂峰),张贵星),等.肺癌患者全血自由基代谢及其酶类测定*[J].郑州大学学报(医学版),2009,(04):766.
 ZHANG Jue),GUO Maofeng),ZHANG Guixing),et al.Detection of free radical metabolism and its protective enzymes of lung carcinoma patients[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(03):766.
[5]刘天舟,张琳,王庆芳,等.血清CEA、NSE、SCCAg和CYFRA211联合检测对肺癌诊断的价值[J].郑州大学学报(医学版),2010,(05):809.
 LIU Tianzhou),ZHANG Lin),WANG Qingfang),et al.Diagnostic value of combined determination of serum CEA,NSE,SCCAg and CYFRA211 for lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(03):809.
[6]齐宇)△,李鑫),杨鲲鹏),等.支气管肺泡灌洗液中CYFRA211、NSE和CEA联合检测对肺癌的诊断价值[J].郑州大学学报(医学版),2010,(04):618.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(03):618.
[7]杜晓光,吕栋,谢新立,等.原发性肺癌合并骨转移242例骨痛分析[J].郑州大学学报(医学版),2010,(04):670.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(03):670.
[8]郑红伟),俞鹏辉),陈勇),等. 中晚期肺癌20例螺旋CT三期动态增强扫描观察[J].郑州大学学报(医学版),2011,(02):276.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(03):276.
[9]任振泰),崔静),李甸源)#,等. 多西紫杉醇对A549细胞的放射增敏作用[J].郑州大学学报(医学版),2011,(02):315.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(03):315.
[10]马群,赵秀升,吕瑞,等. 艾迪注射液联合化疗治疗晚期非小细胞肺癌20例[J].郑州大学学报(医学版),2011,(02):320.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(03):320.

备注/Memo

备注/Memo:

#通讯作者,男,1964年12月生,硕士,主任医师,研究方向:恶性肿瘤与分子靶向治疗,Email:zhangzhongmian@sina.com
更新日期/Last Update: 2013-07-03